Cancer vaccine comprising epitope of c-met and epitope of hif1alpha, and use thereof

Abstract

The present invention relates to: a use of an epitope of c-MET and an epitope of HIF1α as a cancer vaccine; and a use of said cancer vaccine. The cancer vaccine according to the present invention decreases the expression level of HIF1α and/or c-MET and the expression of angiogenesis-related markers in various types of cancer known to overexpress the protein, and can inhibit tumor growth and furthermore, activates T1 cells and induces infiltration of the tumor, and thus can be used as a general-purpose cancer vaccine for suppressing the progression of cancer and preventing the metastasis thereof without being limited to the above-mentioned cancer types. In addition, the vaccine according to the present disclosure can more effectively inhibit the growth and progression of cancer and the formation of metastatic cancer by being administered in combination with an immune checkpoint inhibitor.

Dependencies are inferred from the claim text.